文献速递临床试验与 GCP流行病学与生物统计

印度健康成人中柬埔寨巴斯德研究所与更新版泰国红十字会皮内狂犬病疫苗方案的免疫原性和安全性:一项4期、开放标签、等效性随机对照试验

Immunogenicity and safety of Institut Pasteur du Cambodge (IPC) and updated Thai Red Cross (UTRC) intradermal rabies vaccine regimens among healthy adults in India: A phase 4, open label, equivalence randomised controlled trial.
PubMed 文献 · PLoS Med · 2026-10-29

该4期开放标签随机对照等效性试验在印度健康成人中比较了1周IPC方案与1月UTRC方案的免疫原性和安全性,使用PCECV和PVRV两种疫苗。第42天RVNA的GMR在PCECV为0.59(95%CI 0.47-0.75),PVRV为0.76(95%CI 0.61-0.95),均未达到预设等效标准。所有参与者在第14天至1年各时点RVNA滴度均≥0.5 IU/mL,不良事件轻微且组间相似。

要点

  • IPC方案与UTRC方案在第42天RVNA的GMR未达到预设等效标准。
  • 所有组别参与者从第14天至1年RVNA滴度均≥0.5 IU/mL。
  • 不良事件在方案间相似且大多轻微。

核心结论

  • IPC方案未达到与UTRC方案相比的预设等效标准。
  • 所有参与者在第14天至1年期间均达到提示血清保护的RVNA滴度≥0.5 IU/mL。

研究设计与样本

  • 4期、单中心、开放标签随机对照等效性试验,纳入健康成人志愿者。
  • 参与者按1:1:1:1区组随机分配至PCECV-IPC、PCECV-UTRC、PVRV-IPC和PVRV-UTRC四组,每组100人。
  • IPC方案为第0、3、7天皮内接种,UTRC方案为第0、3、7、28天皮内接种。
  • 主要结局为第42天RVNA的几何平均浓度比(GMR),按疫苗类型分别评估,等效标准为GMR的95%CI完全落在0.72至1.04之间。

主要发现

  • 第42天GMR(IPC vs UTRC)在PCECV为0.59(95%CI 0.47-0.75),在PVRV为0.76(95%CI 0.61-0.95)。
  • 所有四组参与者在第14、28、42、90、180和365天RVNA滴度均≥0.5 IU/mL, regardless of baseline serostatus。
  • 不良事件在方案间相似且大多轻微。

关键数值与推荐

  • 等效标准预设为GMR的95%CI完全位于0.72至1.04之间。
  • 血清保护阈值定义为RVNA滴度≥0.5 IU/mL。

临床怎么用

  • 政策决策在考虑替代UTRC方案时,应结合免疫原性发现、依从性、成本和疫苗可获得性。
  • 在常规暴露后预防设置中应用该结果需谨慎,因试验对象为健康志愿者而非动物咬伤后接受PEP者。

局限性

  • 近四分之一参与者基线RVNA滴度≥0.5 IU/mL,提示可能存在未识别的既往免疫 priming,可能影响GMC估计。
  • 试验在健康志愿者中进行而非动物咬伤后接受PEP者,结果可能不完全反映常规暴露后设置中的疫苗性能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Shorter rabies post-exposure prophylaxis (PEP) regimens could improve compliance and access by reducing the number of clinic visits and vaccine requirement per patient. We compared the immunogenicity and safety of a 1-week intradermal Institut Pasteur du Cambodge (IPC) regimen with a 1-month intradermal Updated Thai Red Cross regimen (UTRC) using two rabies vaccines widely used in India: Purified Chick Embryo Cell vaccine (PCECV) and the Purified Vero Cell Rabies vaccine (PVRV). METHODS AND FINDINGS: We conducted a phase 4, single-centre, open-label randomised controlled equivalence trial among adult healthy volunteers. Participants were block randomised (1:1:1:1) to receive either the IPC (Days 0, 3, 7) or UTRC (Days 0, 3, 7, 28) intradermal regimen with either PCECV or the PVRV. Rabies virus neutralizing antibody (RVNA) titres were measured up to 1 year. The primary objective of the trial was to determine the immunogenicity of the Intradermal abridged Cambodia regimen with updated intradermal Thai red cross regimen using two different vaccine types among healthy volunteers in India. The primary outcome was geometric mean concentration ratios (GMR) of RVNA on day 42, assessed separately for each vaccine type. Equivalence for each vaccine was predefined as the entire 95% confidence interval for GMR lying between 0.72 and 1.04. The secondary outcomes included proportion of participants with RVNA titres >= 0.5 IU/mL on Days 14, 28, 42, 90, 180, and 365 and vaccine safety. Between October 10, 2023, and December 23, 2023, 400 participants were randomly assigned (100 per group) to PCECV-IPC, PCECV-UTRC, PVRV-IPC, and PVRV-UTRC. 362 (90.5%) completed PEP regimen and blood draw on day 42. In the prespecified modified intention-to-treat analysis, the Day 42 GMR (IPC vs UTRC) was 0.59 (95% CI: 0.47-0.75) for PCECV and 0.76 (95% CI: 0.61-0.95) for PVRV, which did not meet the prespecified equivalence criterion. All participants, irrespective of baseline serostatus, in four groups had RVNA titres ≥0.5 IU/ml at every assessment from day 14-1 year. Adverse events were similar between regimens and mostly mild. There are important limitations in this study. Nearly one-quarter of participants had baseline RVNA titres ≥0.5 IU/mL despite exclusion of participants with a reported history of rabies vaccination or dog bite, suggesting unrecognised prior immunological priming that may have influenced GMC estimates. As the trial was conducted among healthy volunteers rather than people receiving PEP after animal bites, the findings may not fully reflect vaccine performance in routine post-exposure settings. CONCLUSION: The IPC regimen did not meet the prespecified equivalence criterion compared to UTRC. All participants achieved RVNA titres ≥0.5 IU/ml indicative of seroprotection from day 14 till 1 year. Policy decisions regarding replacement of UTRC should consider these immunogenicity findings together with compliance, cost, and vaccine availability. TRIAL REGISTRATION: The trial was registered with the Clinical Trial Registry - India (CTRI/2023/10/058418). URL: https://ctri.nic.in/Clinicaltrials/pmaindet2.php?EncHid=OTAxMDA=&Enc=&userName=).

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Thangaraj JWV, Ullas PT, More BD, et al. Immunogenicity and safety of Institut Pasteur du Cambodge (IPC) and updated Thai Red Cross (UTRC) intradermal rabies vaccine regimens among healthy adults in India: A phase 4, open label, equivalence randomised controlled trial. PLoS Med. 2026. PMID: 42956084. doi:10.1371/journal.pmed.1005079

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。